Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER

06/01/2021 | 05:06am EDT

NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the "Company") (NASDAQ: OMER).  Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 20, 2021, Omeros issued a press release "report[ing] that the U.S. Food and Drug Administration (FDA) will require additional time to review the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)."  Omeros advised investors that "[t]he new Prescription Drug User Fee Act (PDUFA) target action date is October 17, 2021." 

On this news, Omeros's stock price fell $1.83 per share, or 10.78% to close at $15.14 on May 20, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

 

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-omeros-corporation---omer-301302632.html

SOURCE Pomerantz LLP


© PRNewswire 2021
All news about OMEROS CORPORATION
06/18OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target
MT
06/16OMEROS : Form 8-K)
PU
06/16OMEROS CORP : Submission of Matters to a Vote of Security Holders, Financial Sta..
AQ
06/15OMEROS' : Narsoplimab pivotal trial data shared in oral presentation at 2021 ann..
AQ
06/14OMEROS : rsquo; Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 20..
BU
06/14Omeros Corporation Announces Narsoplimab Pivotal Trial Data in Oral Presentat..
CI
06/10OMEROS : Announces Publication Detailing the Mechanism of Action of PDE7 In Nico..
BU
06/09OMEROS : to Present at the BofA 2021 Napa BioPharma Virtual Conference
BU
06/09OMEROS : Says OMS906 Was Well-Tolerated in Phase 1 Trial in Alternative Pathway-..
MT
06/09OMEROS : Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
BU
More news